|1.||Chalmers, John: 35 articles (01/2015 - 05/2003)|
|2.||Woodward, Mark: 31 articles (01/2015 - 05/2003)|
|3.||Ferrari, Roberto: 29 articles (12/2015 - 01/2005)|
|4.||Simoons, Maarten L: 20 articles (12/2015 - 07/2005)|
|5.||Neal, Bruce: 18 articles (10/2014 - 05/2003)|
|6.||MacMahon, Stephen: 16 articles (01/2015 - 05/2003)|
|7.||Remme, Willem J: 15 articles (12/2015 - 05/2002)|
|8.||Patel, Anushka: 15 articles (10/2014 - 01/2005)|
|9.||Arima, Hisatomi: 14 articles (10/2014 - 10/2005)|
|10.||PROGRESS Collaborative Group: 13 articles (08/2011 - 09/2001)|
09/01/2011 - "The Perindopril Protection Against Recurrent Stroke Study (PROGRESS) was a randomized placebo-controlled trial which clearly demonstrated that perindopril-based blood pressure (BP)-lowering treatment is one of the most effective and generalizable strategies for secondary prevention of stroke. "
06/01/2006 - "The Perindopril Protection Against Recurrent Stroke Study (PROGRESS) was a randomized, placebo-controlled trial that established the beneficial effects of BP lowering in 6105 patients with cerebrovascular disease. "
10/01/2005 - "This study was a subsidiary analysis of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS)--a randomized, placebo-controlled trial that established the beneficial effects of blood pressure--lowering in a heterogeneous group of patients with cerebrovascular disease. "
01/01/2001 - "Perindopril 4 to 8 mg once daily significantly decreased carotid-femoral aortic pulse wave velocity (PWV), improved arterial compliance, reduced left ventricular mass index and, in patients with recent cerebral ischaemia and/or stroke, preserved cerebral blood flow despite significantly reducing SBP and DBP. "
12/01/1996 - "Chronic treatment with perindopril is beneficial for the prevention of stroke in SPSHR, through the preservation of the myogenic response properties of the cerebral arteries, and the attenuation of tissue damage in the brain and kidneys."
|2.||Hypertension (High Blood Pressure)
08/01/1996 - "Perindopril fully prevented the development of hypertension in LH rats, suppressed their preglomerular vasoconstriction, and markedly improved their pressure-natriuresis. "
01/01/2001 - "Results from ongoing studies will help confirm the place of perindopril in the treatment of hypertension; currently, it is an effective and well tolerated treatment for patients with mild to moderate essential hypertension."
08/01/1994 - "This trial shows that ACE-inhibition with perindopril represents a simple, safe, and effective short-term therapeutic option for the large proportion of patients with mild essential hypertension and concomitant diseases and therapies."
01/01/2001 - "Perindopril monotherapy was also effective in the elderly and in patients with hypertension and concomitant disease. "
04/01/1995 - "A 12-week treatment of adult SHR with perindopril was effective in causing a permanent prevention of hypertension, amelioration of some of the tissue damage associated with hypertension and an increase in the lifespan of these rats."
|3.||Coronary Artery Disease (Coronary Atherosclerosis)
09/06/2003 - "Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)."
04/01/2007 - "Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease."
12/01/2015 - "Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis."
07/01/2013 - "The purpose of the present study was to develop and validate risk prediction models for various cardiovascular end points in the EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) database, consisting of 12,218 patients with established coronary artery disease, with a median follow-up of 4.1 years. "
08/01/2010 - "This article summarizes the recent findings of the PERGENE study and pharmacogenetic research of the treatment benefit of perindopril in stable coronary artery disease."
10/01/2006 - "However, improved symptoms and exercise capacity and fewer hospitalizations for heart failure in the first year were observed on perindopril, during which most patients were on assigned therapy, suggesting that it may be of benefit in this patient population."
01/01/2002 - "In randomised, double-blind, placebo-controlled clinical trials conducted over 3 months and a large noncomparative study (up to 30 months), perindopril 4mg once daily significantly increased exercise tolerance and reduced symptoms of heart failure in patients with mild to moderate CHF. "
01/01/2002 - "Perindopril 4mg significantly improved a range of haemodynamic parameters in single-dose and long-term (8 weeks and 3 months) studies involving patients with congestive heart failure (CHF), with little or no effect on blood pressure or heart rate. "
01/01/2003 - "An efficient dose for heart failure is simply and safely obtained with perindopril, with a significant improvement in the NYHA functional class and in the radiological cardio-thoracic index."
06/01/2001 - "In patients with chronic heart failure, long-term therapy with the ACE inhibitor perindopril improved respiratory muscle strength, as indicated by significant increases in PImax and PEmax."
|5.||Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
12/01/1994 - "This study was designed to assess the course of left ventricular mass by echocardiography in a population of 893 hypertensive patients with moderate left ventricular hypertrophy, treated with perindopril for 3 months. "
01/01/2006 - "2. The treatment with perindopril decreases blood pressure effectively independent of ACE gene I/D genotype and left ventricular hypertrophy. "
01/01/2006 - "2. The analysis of changes in haemostasis and RAS during treatment with perindopril in relation to left ventricular hypertrophy (group LVH+ and LVH-). "
10/04/2001 - "Perindopril increases arterial compliance and reverses left ventricular hypertrophy in hypertensive patients. "
08/01/1994 - "Both treatments lowered systolic blood pressure and reversed left ventricular hypertrophy, perindopril being slightly more efficient at the dose administered. "
|2.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|10.||Calcium Channels (Calcium Channel)
|3.||Drug Therapy (Chemotherapy)
|4.||Homologous Transplantation (Allograft)